Alemtuzumab therapy in T-cell prolymphocytic leukemia: Comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route

Blood

Volumn 118, Issue 22, 2011, Pages 5799-5802

  Dearden, Claire E ^a   Khot, Amit ^a   Else, Monica ^b   Hamblin, Mike ^c   Grand, Effie ^d   Roy, Ashok ^e   Hewamana, Saman ^a   Matutes, Estella ^a   Catovsky, Daniel ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c O and G   (United Kingdom)

^d SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^e BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; PENTOSTATIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; PROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; TREATMENT RESPONSE; VIRUS REACTIVATION;

EID: 82155201714     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-372854     Document Type: Article

References (11)

1. Matutes E, Brito-Babapulle V, Swansbury J, et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78(12):3269- 3274.
2. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol. 1997;15(7):2667-2672. (Pubitemid 27289899)
3. Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood. 2001;98(6):1721-1726.
4. Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002;20(1):205-213. (Pubitemid 34032613)
5. Hopfinger G, Busch R, Eichhorst B, et al. TPLL-1 protocol of the German CLL Study Group (GCLLSG): a prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL [abstract]. Blood. 2007;110(11). Abstract 2039.
6. Ravandi F, Aribi A, O'Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009;27(32):5425-5430.
7. Krishnan B, Else M, Tjonnfjord GE, et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010;149(6):907-910.
8. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100(3):768-773. (Pubitemid 34832599)
9. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27(24):3994-4001.
10. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood. 2004;104(4):948-955. (Pubitemid 39043667)
11. Montagna M, Montillo M, Avanzini MA, et al. Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia. Haematologica. 2011;96(6):932-936.